Drug Profile
Research programme: glycogen synthase kinase 3 inhibitors - Chiron
Alternative Names: CHIR 118637; CHIR 9803; CT 98023; CY 20026; Glycogen synthase kinase 3 inhibitors research programme - ChironLatest Information Update: 29 Aug 2003
Price :
$50
*
At a glance
- Originator Chiron Corporation
- Class
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 29 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 29 Oct 2002 A preclinical study has been added to the Diabetes pharmacodynamics and pharmacokinetics sections
- 20 Dec 2000 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)